siRNA microbicides for preventing and treating diseases
    1.
    发明授权
    siRNA microbicides for preventing and treating diseases 有权
    用于预防和治疗疾病的siRNA杀微生物剂

    公开(公告)号:US07943589B2

    公开(公告)日:2011-05-17

    申请号:US11916334

    申请日:2006-06-05

    摘要: The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally.

    摘要翻译: 本发明提供包含至少一种siRNA的杀微生物组合物。 siRNA是由一个或两个分子制成的RNA双链体。 siRNA的一部分与病毒的必需基因中的靶序列相同。 病毒可以是疱疹病毒,例如HSV-1或HSV-2。 优选地,疱疹病毒是HSV-2。 杀微生物组合物还包含药学上可接受的载体。 本发明还包括通过施用杀微生物剂组合物预防和治疗病毒感染的方法。 优选地,所述杀微生物组合物经粘膜给药。

    siRNA MICROBICIDES FOR PREVENTING AND TREATING DISEASES
    2.
    发明申请
    siRNA MICROBICIDES FOR PREVENTING AND TREATING DISEASES 审中-公开
    用于预防和治疗疾病的siRNA微生物剂

    公开(公告)号:US20120087973A1

    公开(公告)日:2012-04-12

    申请号:US13069589

    申请日:2011-03-23

    摘要: The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally.

    摘要翻译: 本发明提供包含至少一种siRNA的杀微生物组合物。 siRNA是由一个或两个分子制成的RNA双链体。 siRNA的一部分与病毒的必需基因中的靶序列相同。 病毒可以是疱疹病毒,例如HSV-1或HSV-2。 优选地,疱疹病毒是HSV-2。 杀微生物组合物还包含药学上可接受的载体。 本发明还包括通过施用杀微生物剂组合物预防和治疗病毒感染的方法。 优选地,所述杀微生物组合物经粘膜给药。

    siRNA MICROBICIDES FOR PREVENTING AND TREATING DISEASES
    3.
    发明申请
    siRNA MICROBICIDES FOR PREVENTING AND TREATING DISEASES 有权
    用于预防和治疗疾病的siRNA微生物剂

    公开(公告)号:US20090022783A1

    公开(公告)日:2009-01-22

    申请号:US11916334

    申请日:2006-06-05

    摘要: The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally.

    摘要翻译: 本发明提供包含至少一种siRNA的杀微生物组合物。 siRNA是由一个或两个分子制成的RNA双链体。 siRNA的一部分与病毒的必需基因中的靶序列相同。 病毒可以是疱疹病毒,例如HSV-1或HSV-2。 优选地,疱疹病毒是HSV-2。 杀微生物组合物还包含药学上可接受的载体。 本发明还包括通过施用杀微生物剂组合物预防和治疗病毒感染的方法。 优选地,所述杀微生物组合物经粘膜给药。

    Herpesvirus replication defective mutants
    7.
    发明授权
    Herpesvirus replication defective mutants 失效
    疱疹病毒复制缺陷突变体

    公开(公告)号:US07223411B1

    公开(公告)日:2007-05-29

    申请号:US08278601

    申请日:1994-07-21

    IPC分类号: A61K39/245

    摘要: A herpesvirus vaccine comprising a mutated herpesvirus suspended in a pharmaceutically acceptable carrier. The mutated herpesvirus is capable of infecting cells of the mammal to be vaccinated, but incapable of completing a replicative cycle, and it is capable of eliciting a protective immune response in that mammal. The mutated herpesvirus is also capable of treating immunomodulatory or immunoregulatory diseases. The mutation occurs in at least one gene encoding a protein essential for replication of the virus, so that the mutation renders the virus replication defective.

    摘要翻译: 一种疱疹病毒疫苗,其包含悬浮在药学上可接受的载体中的突变疱疹病毒。 突变的疱疹病毒能够感染待接种的哺乳动物的细胞,但不能完成复制循环,并且能够在该哺乳动物中引发保护性免疫应答。 突变的疱疹病毒也能够治疗免疫调节或免疫调节疾病。 该突变发生在编码病毒复制必需蛋白质的至少一个基因中,从而导致病毒复制有缺陷。